Impact of methodology and assumptions in a cost-effectiveness analysis on transcatheter aortic valve replacement  by Osnabrugge, Ruben L.J. & Kappetein, A. Pieter
LETTERS TO THE EDITORIMPACT OF METHODOLOGY
AND ASSUMPTIONS IN A COST-
EFFECTIVENESS ANALYSIS ON
TRANSCATHETER AORTIC
VALVE REPLACEMENT
To the Editor:
With great interest we read the re-
cent article on cost-effectiveness of
transcatheter aortic valve implanta-
tion (TAVI) by Doble and colleagues.1
We congratulate Doble and col-
leagues1 on their well-designed anal-
ysis of this timely and important
topic. They reported a base case
incremental cost-effectiveness ratio
(ICER) of $51,324/quality-adjusted
life-year for TAVI versus standard
management in surgically inoperable
patients. In high-risk patients, TAVI
was economically dominated by
surgical aortic valve replacement
(SAVR). Doble and colleagues1 con-
cluded that TAVI is a cost-effective
treatment option for inoperable pa-
tients but not for high-risk patients.
However, some methodologic issues
and questionable assumptions influ-
enced this conclusion.
The quality-of-life utilities in the
article of Doble and colleagues1were
based on a conversion of New York
Heart Association functional classes,
although direct EQ-5D utilities from
the PARTNER (Placement of Aortic
Transcatheter Valve) trial have been
available since their presentation No-
vember 7, 2011, at the Transcatheter
Cardiovascular Therapeutics 2011 In-
terventional Conference in San Fran-
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The Journaltransfemoral route is associated with
improved quality of life compared to
surgery, whereas the same has not
been demonstrated for the transapical
route.3 Doble and colleagues1 lumped
the quality-of-life improvement with
these 2 distinct techniques together
and reported 0.102 less quality-
adjusted life years after TAVI than
after SAVR. This decrease is incon-
sistent with the quality-of-life results
of transfemoral TAVI in the PART-
NER trial, and its use resulted in
a too pessimistic ICER for TAVI ver-
sus SAVR in high-risk patients.
Doble and colleagues1 used Cana-
dian life tables to simulate long-term
survival in all treatment groups,
whereas a survival comparable to that
of the general population is highly un-
likely.4 Table 2 in the article of Doble
and colleagues1 shows that the method
for extrapolating survival had a large
influence on the ICER of TAVI versus
SAVR. A better approach would have
been to fit survival curves separately
for the treatment groups with Weibull,
log-normal, and other models. In that
way comorbidities such as diabetes
mellitus, coronary artery disease, and
previous myocardial infarction could
have been taken into account as
covariables.
The inputs for the model came from
a variety of sources, and some assump-
tions are questionable. Although unad-
justed costs of balloon valvuloplasty
were directly plugged in from a 23-
year-old study, Figure 2 in the article1
showed that these costs actually have
a major influence on overall cost-
effectiveness. Also, the investigators
used an excessive 36-day hospital
stay after SAVR and based the proce-
dural costs of SAVR on those for sep-
tuagenarians, rather than high-risk
octogenarians. Furthermore, the short-
term probability of acute kidney injury
was estimated at 0.112, whereas 0.011
seems appropriate according to the
PARTNER cohort B data.5
Doble and colleagues1 mentioned
that the ICER of TAVI versus SAVR
would have been more favorableof Thoracic and Cardiovascular Surgetoward TAVI if the costs of the TAVI
procedure had been lower. It would
have been interesting if they had re-
ported what the price of a TAVI valve
would need to be for it to be a cost-
effective alternative to SAVR.6 Also,
an elaboration on the differences with
the PARTNER cost-effectiveness
analyses would have been valuable.
Methodology and assumptions in-
fluence the estimated outcomes in
cost-effectiveness analyses. It would
be interesting to see what the
impact of our remarkswould be in a re-
analysis of the cost-effectiveness esti-
mates of TAVI.
Ruben L. J. Osnabrugge, MSc
A. Pieter Kappetein, MD, PhD
Department of Cardio-Thoracic
Surgery
Erasmus University Medical Center
Rotterdam, The Netherlands
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